Vitamin Shoppe (VSI) Receives Coverage Optimism Rating of 0.01

Media headlines about Vitamin Shoppe (NYSE:VSI) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vitamin Shoppe earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave media coverage about the specialty retailer an impact score of 47.336237362825 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several analysts recently issued reports on the company. Morgan Stanley set a $8.00 target price on Vitamin Shoppe and gave the company a “hold” rating in a research note on Thursday, August 10th. Goldman Sachs Group restated a “sell” rating and set a $6.00 price target (down previously from $13.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Barclays cut their price target on Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a report on Thursday, November 9th. TheStreet cut Vitamin Shoppe from a “c-” rating to a “d” rating in a report on Wednesday, August 9th. Finally, Deutsche Bank restated a “hold” rating and set a $7.00 price target (down previously from $14.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $5.00.

Shares of Vitamin Shoppe (VSI) opened at $3.85 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.32 and a current ratio of 2.07. The firm has a market capitalization of $87.52, a PE ratio of 3.92 and a beta of 0.69. Vitamin Shoppe has a one year low of $2.95 and a one year high of $26.25.

Vitamin Shoppe (NYSE:VSI) last issued its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.20). The company had revenue of $288.20 million during the quarter, compared to analysts’ expectations of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The firm’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.50 EPS. equities research analysts forecast that Vitamin Shoppe will post 0.44 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Vitamin Shoppe (VSI) Receives Coverage Optimism Rating of 0.01” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/05/vitamin-shoppe-vsi-receives-coverage-optimism-rating-of-0-01.html.

About Vitamin Shoppe

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Insider Buying and Selling by Quarter for Vitamin Shoppe (NYSE:VSI)

What are top analysts saying about Vitamin Shoppe Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vitamin Shoppe Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit